Migalastat is an alpha-galactosidase A chaperone medication primarily indicated for the treatment of Fabry disease in patients with amenable galactosidase alpha gene (GLA) variants, where it functions… Read more













Migalastat is an alpha-galactosidase A chaperone medication primarily indicated for the treatment of Fabry disease in patients with amenable galactosidase alpha gene (GLA) variants, where it functions by stabilizing mutant enzyme activity to facilitate proper lysosomal trafficking. Pharmaceutical laboratories utilize this category to access a comprehensive range of reference standards, including the active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, and stable isotope labelled compounds. These materials are essential for robust impurity profiling, method validation, and rigorous quality control protocols. The selection includes structurally related analogs, degradation products—such as specific nitroso and benzyloxy derivatives—and stable isotope labelled Migalastat, which are critical for accuracy in mass spectrometry and chromatographic detection. By employing these standards, analytical teams can identify and characterize degradants formed under stress conditions, ensuring consistent drug safety and compliance with international regulatory guidelines.